View in EDS

Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.

Saved in:
Bibliographic Details
Title: Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.
Authors: GomezMancilla B; Novartis Institutes for BioMedical Research, Basel, Switzerland., Meriggioli MN; Novartis Biomedical Research, Cambridge, MA, USA. Electronic address: matthew.meriggioli@novartis.com., Genge A; Montreal Neurological Institute and Hospital, Montreal, Canada., Roubenoff R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Espié P; Novartis Institutes for BioMedical Research, Basel, Switzerland., Dupuy C; Novartis Institutes for BioMedical Research, Basel, Switzerland., Hartmann N; Novartis Institutes for BioMedical Research, Basel, Switzerland., Pezous N; Novartis Institutes for BioMedical Research, Basel, Switzerland., Kinhikar A; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Tichy M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Dionne A; CHU de Quebec Universite Laval, Quebec, Canada., Vissing J; Rigshospitalet, University of Copenhagen, Denmark., Andersen H; Aarhus University Hospital, Aarhus, Denmark., Schoser B; Friedrich-Baur-Institute, Dep. of Neurology, LMU Klinikum Muenchen, Muenchen, Germany., Meisel A; Charité Universitätsmedizin Berlin, Department of Neurology, Germany., Jordan B; Department of Neurology, University Hospital of Halle, Halle, Germany; epartment of Neurology, University Hospital of Heidelberg, Heidelberg, Germany., Devlikamova F; Republican Clinical Hospital of Medical Rehabilitation, Kazan, Russia., Poverennova I; Samara Regional Clinical Hospital named after M.I.Kalinin, Samara, Russia., Stuchevskaya F; City Multi-specialty Hospital, St. Petersburg, Russia., Lin TS; National Cheng Kung University Hospital, Tainan, Taiwan., Rush JS; Novartis Institutes for BioMedical Research, Basel, Switzerland; Kling Biotherapeuetics BV, Amsterdam, the Netherlands., Gergely P; Novartis Institutes for BioMedical Research, Basel, Switzerland.
Source: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia [J Clin Neurosci] 2024 Jan; Vol. 119, pp. 76-84. Date of Electronic Publication: 2023 Nov 20.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Churchill Livingstone Country of Publication: Scotland NLM ID: 9433352 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2653 (Electronic) Linking ISSN: 09675868 NLM ISO Abbreviation: J Clin Neurosci Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37988976
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22GomezMancilla+B%22">GomezMancilla B</searchLink>; Novartis Institutes for BioMedical Research, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Meriggioli+MN%22">Meriggioli MN</searchLink>; Novartis Biomedical Research, Cambridge, MA, USA. Electronic address: matthew.meriggioli@novartis.com.<br /><searchLink fieldCode="AU" term="%22Genge+A%22">Genge A</searchLink>; Montreal Neurological Institute and Hospital, Montreal, Canada.<br /><searchLink fieldCode="AU" term="%22Roubenoff+R%22">Roubenoff R</searchLink>; Novartis Institutes for BioMedical Research, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Espié+P%22">Espié P</searchLink>; Novartis Institutes for BioMedical Research, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Dupuy+C%22">Dupuy C</searchLink>; Novartis Institutes for BioMedical Research, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Hartmann+N%22">Hartmann N</searchLink>; Novartis Institutes for BioMedical Research, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Pezous+N%22">Pezous N</searchLink>; Novartis Institutes for BioMedical Research, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kinhikar+A%22">Kinhikar A</searchLink>; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Tichy+M%22">Tichy M</searchLink>; Novartis Institutes for BioMedical Research, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Dionne+A%22">Dionne A</searchLink>; CHU de Quebec Universite Laval, Quebec, Canada.<br /><searchLink fieldCode="AU" term="%22Vissing+J%22">Vissing J</searchLink>; Rigshospitalet, University of Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Andersen+H%22">Andersen H</searchLink>; Aarhus University Hospital, Aarhus, Denmark.<br /><searchLink fieldCode="AU" term="%22Schoser+B%22">Schoser B</searchLink>; Friedrich-Baur-Institute, Dep. of Neurology, LMU Klinikum Muenchen, Muenchen, Germany.<br /><searchLink fieldCode="AU" term="%22Meisel+A%22">Meisel A</searchLink>; Charité Universitätsmedizin Berlin, Department of Neurology, Germany.<br /><searchLink fieldCode="AU" term="%22Jordan+B%22">Jordan B</searchLink>; Department of Neurology, University Hospital of Halle, Halle, Germany; epartment of Neurology, University Hospital of Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Devlikamova+F%22">Devlikamova F</searchLink>; Republican Clinical Hospital of Medical Rehabilitation, Kazan, Russia.<br /><searchLink fieldCode="AU" term="%22Poverennova+I%22">Poverennova I</searchLink>; Samara Regional Clinical Hospital named after M.I.Kalinin, Samara, Russia.<br /><searchLink fieldCode="AU" term="%22Stuchevskaya+F%22">Stuchevskaya F</searchLink>; City Multi-specialty Hospital, St. Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Lin+TS%22">Lin TS</searchLink>; National Cheng Kung University Hospital, Tainan, Taiwan.<br /><searchLink fieldCode="AU" term="%22Rush+JS%22">Rush JS</searchLink>; Novartis Institutes for BioMedical Research, Basel, Switzerland; Kling Biotherapeuetics BV, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Gergely+P%22">Gergely P</searchLink>; Novartis Institutes for BioMedical Research, Basel, Switzerland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229433352%22">Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia</searchLink> [J Clin Neurosci] 2024 Jan; Vol. 119, pp. 76-84. <i>Date of Electronic Publication: </i>2023 Nov 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Churchill+Livingstone%22">Churchill Livingstone </searchLink><i>Country of Publication: </i>Scotland <i>NLM ID: </i>9433352 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-2653 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209675868%22">09675868 </searchLink><i>NLM ISO Abbreviation: </i>J Clin Neurosci <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37988976
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jocn.2023.11.013
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 76
    Titles:
      – TitleFull: Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: GomezMancilla B
      – PersonEntity:
          Name:
            NameFull: Meriggioli MN
      – PersonEntity:
          Name:
            NameFull: Genge A
      – PersonEntity:
          Name:
            NameFull: Roubenoff R
      – PersonEntity:
          Name:
            NameFull: Espié P
      – PersonEntity:
          Name:
            NameFull: Dupuy C
      – PersonEntity:
          Name:
            NameFull: Hartmann N
      – PersonEntity:
          Name:
            NameFull: Pezous N
      – PersonEntity:
          Name:
            NameFull: Kinhikar A
      – PersonEntity:
          Name:
            NameFull: Tichy M
      – PersonEntity:
          Name:
            NameFull: Dionne A
      – PersonEntity:
          Name:
            NameFull: Vissing J
      – PersonEntity:
          Name:
            NameFull: Andersen H
      – PersonEntity:
          Name:
            NameFull: Schoser B
      – PersonEntity:
          Name:
            NameFull: Meisel A
      – PersonEntity:
          Name:
            NameFull: Jordan B
      – PersonEntity:
          Name:
            NameFull: Devlikamova F
      – PersonEntity:
          Name:
            NameFull: Poverennova I
      – PersonEntity:
          Name:
            NameFull: Stuchevskaya F
      – PersonEntity:
          Name:
            NameFull: Lin TS
      – PersonEntity:
          Name:
            NameFull: Rush JS
      – PersonEntity:
          Name:
            NameFull: Gergely P
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2024 Jan
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1532-2653
          Numbering:
            – Type: volume
              Value: 119
          Titles:
            – TitleFull: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
              Type: main
ResultId 1